New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies

Produk Detail:
  • Author : Anonim
  • Publisher : Academic Press
  • Pages : 250 pages
  • ISBN : 0128167378
  • Rating : /5 from reviews
CLICK HERE TO GET THIS BOOK >>>New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies

Download or Read online New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies full in PDF, ePub and kindle. this book written by Anonim and published by Academic Press which was released on 01 November 2020 with total page 250 pages. We cannot guarantee that New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies book is available in the library, click Get Book button and read full online book in your kindle, tablet, IPAD, PC or mobile whenever and wherever You Like. New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies provides general updated information on the resistance of various human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It discusses also the description of various targeted sensitizing agents that can reverse innate or acquired resistance when used in combination with various FDA-approved anti-CD20 antibodies. There have been a lot of reports in which the treatment with anti-CD20 antibodies for various lymphomas/leukemias has resulted in significant clinical responses; however, there have been also subsets of cancer patients who did not respond initially and several of the responding patients developed resistance to subsequent treatments with the same or different regimens. Therefore, the use of various immunosensitizing agents targeting resistant factors to reverse resistance has been considered and this book discusses each of them in depth, such as Bortexomib, Immunomodulation Agents, Obinutuzumab, Tumor Suppressors, and HDAC Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to anti-CD20 antibodies. Provides a general overview of various sensitizing agents that can work effectively when used in combination with anti-CD20 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to further antibody treatments Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies

New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies
  • Author : Anonim
  • Publisher : Academic Press
  • Release : 01 November 2020
GET THIS BOOK New Combination Approaches to Enhance Rituximab Based Lymphoma Therapies

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies provides general updated information on the resistance of various human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It discusses also the description of various targeted sensitizing agents that can reverse innate or acquired resistance when used in combination with various FDA-approved anti-CD20 antibodies. There have been a lot of reports in which the treatment with anti-CD20 antibodies for various lymphomas/leukemias has resulted in significant clinical responses; however, there have been also

Resistance to Targeted Therapies in Lymphomas

Resistance to Targeted Therapies in Lymphomas
  • Author : Ana C. Xavier,Mitchell S. Cairo
  • Publisher : Springer Nature
  • Release : 13 September 2019
GET THIS BOOK Resistance to Targeted Therapies in Lymphomas

Over the past few decades, lymphoma patient outcomes have improved as a result of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems. Even more recently, there has been tremendous progress in the understanding of cancer cell biology and its microenvironment which has resulted in the development of biologic agents, also called "target" therapies. These therapies are more specific in targeting cancer cells either directly or via enhancement of the immune

The Lymphoid Neoplasms 3ed

The Lymphoid Neoplasms 3ed
  • Author : Ian Magrath
  • Publisher : CRC Press
  • Release : 30 July 2010
GET THIS BOOK The Lymphoid Neoplasms 3ed

This comprehensive and authoritative reference covers all aspects of the group of disorders collectively known as the lymphoid neoplasms. The reader is taken through a description of its normal cellular origins and the molecular genetic abnormalities that can lead to this group of conditions, a section of the book that has been considerably strengthened for this third edition, to the environmental factors that may be relevant to disease development, and, finally, to the pragmatic aspects of disease management. The authors

Living with Lymphoma

Living with Lymphoma
  • Author : Elizabeth M. Adler
  • Publisher : JHU Press
  • Release : 30 September 2005
GET THIS BOOK Living with Lymphoma

When neurobiologist Elizabeth M. Adler was diagnosed with non-Hodgkin's lymphoma, she learned everything she could about the disease. In "Living with Lymphoma," she combines her knowledge of lymphoma--both scientific and personal--with the desire to help other patients come to grips with this complex, and often baffling, disease. Readers gain sufficient background to understand and evaluate medical literature, and to ask their physicians questions specific to their own needs.

Perry s The Chemotherapy Source Book

Perry s The Chemotherapy Source Book
  • Author : Michael C. Perry,Donald C. Doll,Carl E. Freter
  • Publisher : Lippincott Williams & Wilkins
  • Release : 30 July 2012
GET THIS BOOK Perry s The Chemotherapy Source Book

Perry’s The Chemotherapy Source Book, now in its fifth edition, provides information on the choice of chemotherapeutic agents, the use of combination chemotherapy, and the toxicity of individual drugs. Organized by site, this is the only book of its kind to focus strictly on the clinical practice of chemotherapy, and is meant to serve as a “one-stop shop” for information on choice of chemotherapeutic agents, treatment outlines, grading of side effects, and dose modification.

Goldman s Cecil Medicine Expert Consult Premium Edition Enhanced Online Features and Print Single Volume 24

Goldman s Cecil Medicine Expert Consult Premium Edition    Enhanced Online Features and Print  Single Volume 24
  • Author : Russell La Fayette Cecil,Lee Goldman,Andrew I. Schafer
  • Publisher : Elsevier Health Sciences
  • Release : 01 January 2012
GET THIS BOOK Goldman s Cecil Medicine Expert Consult Premium Edition Enhanced Online Features and Print Single Volume 24

Since 1927, Goldman-Cecil Medicine has been the world's most influential internal medicine resource. In the ground-breaking 25th edition, your original purchase ensures you will be up-to-date without the need for a subscription. Through the new, more powerful Expert Consult eBook platform, this "living text" provides continuous updates that will integrate the latest research, guidelines, and treatments into each chapter, ensuring that the content is as current as the day this edition was first published. Goldman-Cecil Medicine offers definitive, unbiased guidance on

Principles of Cancer Biotherapy

Principles of Cancer Biotherapy
  • Author : Robert K. Oldham,Robert O. Dillman
  • Publisher : Springer Science & Business Media
  • Release : 29 August 2009
GET THIS BOOK Principles of Cancer Biotherapy

At the time of the first edition of Principles of Cancer Biotherapy in 1987, this book represented the first comprehensive textbook on biological therapy. In 1991, when the second edition was published, there was still some doubt on the part of many oncologists and cancer researchers as to the therapeutic value of these new approaches. By 2003 and the fourth edition, it was generally agreed that biopharmaceuticals were producing major opportunities for new cancer therapies. Cancer biotherapy has now truly matured into the

Non Hodgkin Lymphoma

Non Hodgkin Lymphoma
  • Author : Andrew M. Evens,Kristie A. Blum
  • Publisher : Springer
  • Release : 06 February 2015
GET THIS BOOK Non Hodgkin Lymphoma

This book provides clinical practitioners and the research community with detailed information on the diagnosis, prognosis, and treatment of non-Hodgkin lymphoma, taking into account the significant growth in knowledge including multiple therapeutic advances that have been achieved over the past 5-10 years. The work is subdivided into epidemiology, pathogenesis, pathology, imaging, and therapy of the non-Hodgkin lymphomas. The full range of therapeutic options are examined according to the major subtypes of non-Hodgkin lymphoma and the most up-to-date information is provided

Drug Benefits and Risks

Drug Benefits and Risks
  • Author : C.J. van Boxtel,B. Santoso,I.R. Edwards
  • Publisher : IOS Press
  • Release : 06 August 2008
GET THIS BOOK Drug Benefits and Risks

This updated and revised 2nd edition of Drug Benefits and Risks is an inclusive reference exploring the scientific basis and practice of drug therapy. The key concept is to look at the balance between the benefits and risks of drugs, but in this context also highlighting the social impact which drugs have in modern societies. Taking an evidence-based approach to the problem, the practice of clinical pharmacology and pharmacotherapy in the developing as well as the developed world is examined.

Combinatorial Approaches to Enhance Anti Tumor Immunity Focus on Immune Checkpoint Blockade Therapy

Combinatorial Approaches to Enhance Anti Tumor Immunity  Focus on Immune Checkpoint Blockade Therapy
  • Author : Patrik Andersson,Christian Ostheimer
  • Publisher : Frontiers Media SA
  • Release : 27 December 2019
GET THIS BOOK Combinatorial Approaches to Enhance Anti Tumor Immunity Focus on Immune Checkpoint Blockade Therapy

The immune system harbors great potential for controlling and eliminating tumors. Recent developments in the field of immuno-oncology has led to unprecedented clinical benefits for a broad spectrum of solid tumors. However, immunotherapy (IT) approaches currently have several limitations including (i) low response rate; (ii) development of resistance and (iii) causing severe immune-related adverse effects (IrAEs), which underline the importance of adequate patient selection. Importantly, IT holds promising synergistic potential when combined with standard-of-care chemotherapy, radiotherapy (RT) and anti-angiogenic therapy (

Methods of Cancer Diagnosis Therapy and Prognosis

Methods of Cancer Diagnosis  Therapy  and Prognosis
  • Author : M. A. Hayat
  • Publisher : Springer Science & Business Media
  • Release : 07 April 2010
GET THIS BOOK Methods of Cancer Diagnosis Therapy and Prognosis

There are more than 100 types of cancers In Part II, head and neck cancer is d- affecting all parts of the human body. cussed. The global number of annual new More than 11 million people are diagnosed cases of this malignancy is ~500,000. These with cancer every year, and it is estimated malignancies include oral squamous cell that there will be 16 million new cases by carcinoma, salivary gland tumors, tons- the year 2020. In 2005, 7. 6 million peo- lar cancer, tongue cancer, nasopharyngeal ple died

Neoplastic Diseases of the Blood

Neoplastic Diseases of the Blood
  • Author : Peter H. Wiernik,John M. Goldman,Janice P. Dutcher,Robert A. Kyle
  • Publisher : Springer Science & Business Media
  • Release : 22 September 2012
GET THIS BOOK Neoplastic Diseases of the Blood

Neoplastic Diseases of the Blood integrates the history, epidemiology, pathology, pathophysiology, and therapeutics of modern neoplastic hematopathology. The book is divided into five major sections, with the first four covering the spectrum of hematologic neoplasia— Chronic Leukemias and Related Disorders , Acute Leukemias, Myeloma and Related Disorders, and Lymphomas. The fifth section covers a variety of topics in supportive care. Now in its fifth edition, this classic and invaluable text brings together a team of internationally renowned experts and offers in-depth

Antibody Fc

Antibody Fc
  • Author : George J. Weiner
  • Publisher : Elsevier Inc. Chapters
  • Release : 06 August 2013
GET THIS BOOK Antibody Fc

Monoclonal antibodies (mAbs), including rituximab, are now a mainstay in the therapy of cancer. Despite their undeniable therapeutic value, there is much we do not fully understand about the mechanisms of action responsible for their anti-tumor effects. These mechanisms are often studied in isolation. In this chapter, we will review the mechanisms of action of anti-cancer mAbs and discuss how they interact. The focus of this discussion will be on rituximab, but similar conclusions can be reached with other mAbs.

Cancer Immunology

Cancer Immunology
  • Author : Nima Rezaei
  • Publisher : Springer
  • Release : 29 December 2014
GET THIS BOOK Cancer Immunology

This translational book describes in detail the clinical application of novel approaches in cancer immunotherapy with the aim of educating clinicians in the implications of the most recent research and new developments in the field. The scope is broad, encompassing, for example, prognostic biomarkers for personalized cancer treatment, strategies for targeting tumor immunosuppression, gene therapy, virus-based vaccines, targeting of cancer stem cells, hematopoietic stem cell transplantation, the role of T lymphocytes in cancer immunotherapy, use of monoclonal antibodies, and many

Targeted Therapies in Cancer

Targeted Therapies in Cancer
  • Author : Manfred Dietel
  • Publisher : Springer Science & Business Media
  • Release : 10 June 2007
GET THIS BOOK Targeted Therapies in Cancer

From its introduction, oncological chemotherapy has been encumbered by poor selectivity because antiproliferative drugs are often toxic not only to tumor cells but also to important populations of the body’s non-neoplastic cells. Modern targeted therapies interact with defined molecules present on cancer cells, adding increased selectivity to their toxic effects. This book presents an integrated critical view on the theories, mechanisms, problems and pitfalls of the targeted therapy approach.